

ZNHIT3 (E-12): sc-165964

BACKGROUND

ZNHIT3 (zinc finger, HIT-type containing 3), also known as TRIP3 (thyroid receptor-interacting protein 3) or HNF-4 α coactivator, is a 155 amino acid protein that contains one HIT-type zinc finger and regulates PPAR γ -mediated adipocyte differentiation. ZNHIT3 also coactivates HNF-4 α , and as a thyroid receptor interacting protein, ZNHIT3 interacts with the ligand binding domain of the thyroid receptor. The gene encoding ZNHIT3 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

REFERENCES

- Hall, J.M., Friedman, L., Guenther, C., Lee, M.K., Weber, J.L., Black, D.M. and King, M.C. 1992. Closing in on a breast cancer gene on chromosome 17q. *Am. J. Hum. Genet.* 50: 1235-1242.
- Lee, J.W., Choi, H.S., Gyuris, J., Brent, R. and Moore, D.D. 1995. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. *Mol. Endocrinol.* 9: 243-254.
- Evans, S.C. and Lozano, G. 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. *Mol. Med. Today.* 3: 390-395.
- Soussi, T., Dehouche, K. and Bérout, C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum. Mutat.* 15: 105-113.
- Iannone, M.A., Consler, T.G., Pearce, K.H., Stimmel, J.B., Parks, D.J. and Gray, J.G. 2001. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. *Cytometry* 44: 326-337.
- Piura, B., Rabinovich, A. and Yanai-Inbar, I. 2001. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 97: 241-244.
- Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E.H., Ruijtenbeek, R. and Kalkhoven, E. 2009. Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. *Mol. Cell Proteomics.* 8: 2212-2226.
- Zhang, J.B., Li, X.H., Ning, F. and Guo, X.S. 2009. Relationship between expression of GYPC and TRIP3 genes and prognosis of acute lymphoblastic leukemia in children. *Zhongguo Dang Dai Er Ke Za Zhi* 11: 29-32.
- Online Mendelian Inheritance in Man, OMIM[™]. 2011. Johns Hopkins University, Baltimore, MD. MIM Number: 604500: World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>

CHROMOSOMAL LOCATION

Genetic locus: ZNHIT3 (human) mapping to 17q12.

SOURCE

ZNHIT3 (E-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of ZNHIT3 of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-165964 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

ZNHIT3 (E-12) is recommended for detection of ZNHIT3 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other ZNHIT family members.

Suitable for use as control antibody for ZNHIT3 siRNA (h): sc-93964, ZNHIT3 shRNA Plasmid (h): sc-93964-SH and ZNHIT3 shRNA (h) Lentiviral Particles: sc-93964-V.

Molecular Weight of ZNHIT3: 18 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.